The CEO of the Danish drugmaker behind Ozempic and Wegovy, Lars Fruergaard Jørgensen, has resigned from Novo Nordisk today, with the company stating that the departure is part of a “mutual agreement.” Jørgensen agreed to stay on as CEO until a replacement is found.
In a press release, the company stated, “Novo Nordisk has a clear strategy, a strong product portfolio and an experienced leadership team. The changes are, however, made in light of the recent market challenges Novo Nordisk has been facing, and the development of the company’s share price since mid-2024.”
Helge Lund, chair of the Novo Nordisk Board stated, “Novo Nordisk’s strategy remains unchanged, and the Board is confident in the company’s current business plans and its ability to execute on the plans. On behalf of the Board, I would like to thank Lars Fruergaard Jørgensen for his outstanding contributions to Novo Nordisk’s success during his tenure as CEO. He is highly respected both inside and outside the company for his leadership, values and vision for the company and the pharmaceutical industry at large.”
Lars Fruergaard Jørgensen told investors, “Serving as Novo Nordisk’s CEO for the past eight years has been a privilege and an experience that I will always cherish. I am proud of the results I have helped create together with my leadership team, the Board, and the thousands of employees who work every day to drive change to defeat serious chronic diseases.”
Novo Nordisk stock declined 4% following Jørgensen’s resignation.
By CEO NA Editorial Staff
